Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LEGN Stock Price Chart Interactive Chart >
LEGN Price/Volume Stats
|Current price||$40.91||52-week high||$58.00|
|Prev. close||$41.01||52-week low||$30.75|
|Day high||$41.89||Avg. volume||718,883|
|50-day MA||$44.44||Dividend yield||N/A|
|200-day MA||$43.12||Market Cap||6.71B|
Legend Biotech Corp. ADR (LEGN) Company Bio
Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.
Most Popular Stories View All
LEGN Latest News Stream
|Loading, please wait...|
LEGN Latest Social Stream
View Full LEGN Social Stream
Latest LEGN News From Around the Web
Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.
In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech (LEGN - Research Report), with a price target of $77.00. The company's shares opened today at $41.09.According to TipRanks, Biliouris is a 4-star analyst with an average return of 14.6% and a 40.00% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Verve Therapeutics, and Beam Therapeutics.Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $69.00.
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
SOMERSET, N.J., September 27, 2022--Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI™ for the treatment of adults with relapsed or refractory MM.
SOMERSET, N.J., September 15, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please click here to register for the event.
Legend Biotech stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. Is Legend Biotech Stock A Buy?
SOMERSET, N.J., August 19, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:
LEGN Price Returns